<DOC>
	<DOCNO>NCT00659373</DOCNO>
	<brief_summary>RATIONALE : Learning long-term effect adjuvant tamoxifen ( T ) , adjuvant tamoxifen ovarian function suppression ( T+OFS ) , exemestane ovarian function suppression ( E+ OFS ) brain function may help doctor plan cancer treatment . PURPOSE : This study look brain function premenopausal woman receive adjuvant tamoxifen ( T ) alone receive adjuvant tamoxifen ( T+OFS ) exemestane ( E+OFS ) ovarian function suppression ( OFS ) early-stage breast cancer clinical trial IBCSG-2402 .</brief_summary>
	<brief_title>Brain Function Premenopausal Women Receiving Tamoxifen With Without Ovarian Function Suppression Early-Stage Breast Cancer Clinical Trial IBCSG 24-02</brief_title>
	<detailed_description>OBJECTIVES : Primary : * To evaluate compare change cognitive function one year premenopausal breast cancer patient receive adjuvant tamoxifen ( T ) alone receive adjuvant tamoxifen ( T+OFS ) exemestane ( E+OFS ) ovarian function suppression ( OFS ) . OUTLINE : This multicenter study . Objective cognitive function measure CogState computerized test battery . The CogState battery consist seven task : Detection , Identification , Monitoring , Memory , Learning , International Shopping List Task ( ISLT ) , ISLT-Delayed Recall . Performance speed measure Detection , Identification Monitoring task performance accuracy measure Memory , Learning , ISLT , ISLT-Delayed Recall . Measures performance speed normalize use measure performance accuracy ( % ) normalize use arcsine transformation . The main outcome measure composite score average task score ( transformation standardization age-specific norm ) . Patients complete assessment baseline ( i.e . start protocol hormonal therapy ) approximately one year randomization parent IBCSG 24-02 ( SOFT ) study . Data collect separately T+OFS E+OFS participant parent study , IBCSG 24-02 ( SOFT ) . The sample size Co-SOFT substudy small , analysis plan revise pre-specify collective analysis patient receive OFS .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Completely resect disease Registered clinical trial IBCSG2402 , yet start protocol hormonal therapy Has yet receive follow adjuvant endocrine therapy , either registration IBCSG2402 : Tamoxifen , exemestane , gonadotropinreleasing hormone ( GnRH ) agonist Ovarian irradiation Bilateral oophorectomy Hormone receptor status : Estrogen and/or progesterone receptor positive Each tumor must hormone receptor positive PATIENT CHARACTERISTICS : Premenopausal Can speak read local language ( ) fluently PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>fatigue</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>